Compare Amylx Pharmaceuticals Inc (AMLX) vs Invesco DB Commodity Index Tracking Fund (DBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Invesco DB Commodity Index Tracking Fund — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while Invesco DB Commodity Index Tracking Fund trades at $29.97. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Invesco DB Commodity Index Tracking Fund nearer its low. Which is the better fit depends on your goals.
| AMLX | DBC | |
|---|---|---|
Market Cap | $2.53B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $24.19 | $31.69 |
52-Week Low | $7.82 | $21.62 |
Enterprise Value | $2.28B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
DBC trades at $28.91, up 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. Financial ratios are unavailable in the provided data. Recent news highlights commodities ETFs as inflation hedges, with articles discussing portfolio strategies and geopolitical impacts on commodity markets.
The outlook for DBC is clouded by bearish technicals and lack of fundamental data. Commodity market volatility from geopolitical tensions offers potential upside, but investors face risks from unclear financial health and market sentiment shifts. Careful evaluation of upcoming earnings and analyst coverage is essential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →
